SAVARA INC
SVRANASDAQ🏆 #2358 by market capEarnings Nov 5 · PostUS Equity
$5.02▲ $0.15 (+2.98%)
Pre-market · at closeTrack SVRA
Get earnings, price moves & breaking news on Telegram
24h▲ 3.0%
7d▲ 10.7%
14d▲ 5.6%
30d▼ 1.7%
ytd▼ 16.8%
1y▲ 15.6%
🏦Market Cap
$1.03B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
3955.1x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $4.78 – $5.05
- 52-Week Range
- $3.86 – $7.01
- Volume (shares)
- 164,890
- Avg Volume (shares)
- —
- Shares Outstanding
- 205.5M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 3955.1x
- EPS (TTM)
- $-0.58
- Dividend Yield
- —
- Dilution (1yr)
- +12.2%
SAVARA INC
SVRAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$124M▲ +19.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$101M▲ +13.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
222.4M▲ +12.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▲ +$15M YoY
StockOtter · stockotter.spaceAbout SAVARA INC
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.